Home » Stocks » ENLV

Enlivex Therapeutics Ltd. (ENLV)

Stock Price: $10.97 USD -0.26 (-2.32%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $10.90 -0.07 (-0.64%) Apr 16, 6:19 PM
Market Cap 199.96M
Revenue (ttm) n/a
Net Income (ttm) -9.38M
Shares Out 18.23M
EPS (ttm) -0.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $10.97
Previous Close $11.23
Change ($) -0.26
Change (%) -2.32%
Day's Open 11.13
Day's Range 10.75 - 11.28
Day's Volume 85,537
52-Week Range 4.49 - 29.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Enlivex Therapeutics Ltd (NASDAQ: ENLV) and Yale Cancer Center announced a research collaboration to assess the potential of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. A...

3 weeks ago - Benzinga

Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancers that do not respond to stand-alone checkpoint inhibitor therapies. Collaborat...

3 weeks ago - GlobeNewsWire

These 7 risky stocks have solid fundamentals for long term growth. Use their drops now as an entry point into new highs.

Other stocks mentioned: AYX, CLX, KC, MGNI, RKT, U
1 month ago - InvestorPlace

-- Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor therapies ...

1 month ago - GlobeNewsWire

Nes-Ziona, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macropha...

2 months ago - GlobeNewsWire

Nes Ziona, Israel, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients ...

2 months ago - GlobeNewsWire

Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients ...

2 months ago - GlobeNewsWire

Nes Ziona, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients ...

2 months ago - GlobeNewsWire

Nes Ziona, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Compa...

3 months ago - GlobeNewsWire

– Comparison of 10 AllocetraTM-treated patients with 37 matched controls showed significant positive responses in state of organ failure, duration of ICU stay and mortality in a highly fragile and extre...

3 months ago - GlobeNewsWire

Nes Ziona, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported positive interim results of an invest...

4 months ago - GlobeNewsWire

* Significant short and long-term clinical improvement for a hospitalized patient with a rare disease that currently has no effective treatment options *

4 months ago - GlobeNewsWire

* Dr. Schwartz Served as ArQule's Chief Medical Officer and Head of Research and Development Prior to the $2.7 billion Acquisition of ArQule by Merck in February 2020 *

5 months ago - GlobeNewsWire

Nes Ziona, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that it will present the clinical de...

5 months ago - GlobeNewsWire

Nes-Ziona, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that the U.S. Patent and Trademark O...

5 months ago - GlobeNewsWire

Investors will be keen on pipeline updates when Enlivex Therapeutics (ENLV) reports results for the three months ending Sep 30, 2020.

5 months ago - Zacks Investment Research

Nes Ziona, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the Israeli Ministry of Health a...

5 months ago - GlobeNewsWire

Nes Ziona, Israel, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the first two patients have been...

5 months ago - GlobeNewsWire

Nes Ziona, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the Israeli Ministry of Health a...

6 months ago - GlobeNewsWire

Shares of Enlivex Therapeutics Ltd (NASDAQ: ENLV) broke out of a $4-$6 trading range last week and have been seeing strong upward momentum ever since.  A Rally On COVID-19 Data: The catalyst behind the ...

6 months ago - Benzinga

Enlivex just announced that it will launch Phase 2 trials for a plasma-based coronavirus treatment, and ENLV stock is soaring in response. The post ENLV Stock: Why Enlivex Is Soaring 70% Today appeared ...

6 months ago - InvestorPlace

Nes Ziona, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported positive top-line results of an inves...

6 months ago - GlobeNewsWire

Nes-Ziona, Israel, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the China National Intellectual Property Administration (C...

7 months ago - GlobeNewsWire

Nes-Ziona, Israel, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the U.S. Patent and Trademark Office  issued a notice of al...

7 months ago - GlobeNewsWire

- D ata show a 90% decrease in mortality with AllocetraTM treatment in a murine cecal ligation and puncture severe sepsis model

8 months ago - GlobeNewsWire

Nes-Ziona, Israel, June 18, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Japan Patent Office (JPO) has issued a notice of allow...

9 months ago - GlobeNewsWire

Nes Ziona, Israel, June 01, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that management will present a corporate overview...

10 months ago - GlobeNewsWire

Nes Ziona, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that an investigator-initiated multi-center Phase ...

11 months ago - GlobeNewsWire

Nes Ziona, Israel, April 13, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the Israel Innovation Authority (IIA) sele...

1 year ago - GlobeNewsWire

– Final Analysis Comparing 10 AllocetraTM-Treated Patients with 37 Matched Controls Showed Significant Positive Responses in State of Organ Failure, ICU Hospitalization and Mortality in a Highly Fragile...

1 year ago - GlobeNewsWire

Nes-Ziona, March 09, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Israel Patent Office granted a new patent (#239236) covering ...

1 year ago - GlobeNewsWire

Nes-Ziona, Israel, March 05, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced register...

1 year ago - GlobeNewsWire

Regarding Submission of Proposal to the Korean Authorities for Potential Use of Allocetra TM  as Treatment of Patients with Coronavirus Disease (COVID-19) Patients Admitted to ICU

1 year ago - GlobeNewsWire

Nes-Ziona, Israel, March 02, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements w...

1 year ago - GlobeNewsWire

Nes-Ziona, Israel, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced registere...

1 year ago - GlobeNewsWire

Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements wi...

1 year ago - GlobeNewsWire

Shares of Israel-based Enlivex Therapeutics Ltd. ENLV, +4.90% rocketed 53% in active premarket trading Monday, after the clinical-stage immunotherapy company said it has started a plan to increase its m...

1 year ago - Market Watch

Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it is initiating a plan to increase its man...

1 year ago - GlobeNewsWire

Nes-Ziona, Israel, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the company was selected, for a scientific ...

1 year ago - GlobeNewsWire

About ENLV

Enlivex Therapeutics Ltd. operates as a clinical stage macrophage reprogramming immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and various others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherap... [Read more...]

Industry
Biotechnology
IPO Date
Dec 12, 1995
CEO
Dror Mevorach
Employees
36
Stock Exchange
NASDAQ
Ticker Symbol
ENLV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for ENLV stock is "Buy" and the 12-month stock price forecast is 33.00.

Price Target
$33.00
Analyst Consensus: Buy